ライフサイエンスコーパス: type 2 diabetes

1 eral metabolic diseases including obesity or type 2 diabetes.

2 to the development of insulin resistance and type 2 diabetes.

3 c steatohepatitis and cardiovascular risk in type 2 diabetes.

4 ions in an independent case-control study of type 2 diabetes.

5 the liver, leading to insulin resistance and type 2 diabetes.

6 opment of a new proposal aimed at preventing type 2 diabetes.

7 associated with both prevalent and incident type 2 diabetes.

8 r the treatment of chronic kidney disease in type 2 diabetes.

9 rolled despite optimal medical treatment for type 2 diabetes.

10 BCAAs) associate with insulin resistance and type 2 diabetes.

11 of metabolic stress and prevent the onset of type 2 diabetes.

12 ssion of CKD beyond MRE therapy in mice with type 2 diabetes.

13 to reveal new therapeutic opportunities for type 2 diabetes.

14 skeletal muscle is beneficial in obesity and Type 2 diabetes.

15 igative areas into insulin insensitivity and type 2 diabetes.

16 d function is central to the pathogenesis of type 2 diabetes.

17 olygenic risk for coronary heart disease and type 2 diabetes.

18 to the insulin resistance that characterizes type 2 diabetes.

19 e causal association of EIF-4E and EIF-4A on type 2 diabetes.

20 randomized clinical trials of patients with type 2 diabetes.

21 and how they impact beta-cell dysfunction in type 2 diabetes.

22 s consistent among patients with and without type 2 diabetes.

23 treatment of periodontitis in patients with type 2 diabetes.

24 morbidity and mortality in individuals with type 2 diabetes.

25 ociated with coronary heart disease (CHD) in type 2 diabetes.

26 for restoring proper glucose homeostasis in type 2 diabetes.

27 ant clinical question about the treatment of type 2 diabetes.

28 tients with chronic kidney disease (CKD) and type 2 diabetes.

29 keratopathy is an important complication of type 2 diabetes.

30 cated in the pathogenesis of both type 1 and type 2 diabetes.

31 n both healthy individuals and patients with type 2 diabetes.

32 is one of the earliest pathogenic events in type 2 diabetes.

33 umber of AT macrophages (ATMs) and linked to type 2 diabetes.

34 a improved wound healing in a mouse model of type 2 diabetes.

35 role in glucose homeostasis and treatment of type 2 diabetes.

36 ess preference may not have enhanced risk of type 2 diabetes.

37 ssociation of AAI and drinking duration with type 2 diabetes.

38 rongly causal for coronary artery disease or type 2 diabetes.

39 red energy metabolism metabolic syndrome and type 2 diabetes.

40 identified as a top priority by people with type 2 diabetes.

41 ns were supported as having a causal role in type 2 diabetes.

42 r risk factor for metabolic diseases such as type 2 diabetes.

43 hyperinsulinemia precedes the development of type 2 diabetes.

44 actors, including obesity, hypertension, and type 2 diabetes.

45 strong predictability for family history of type 2 diabetes.

46 for the treatment of insulin resistance and type 2 diabetes.

47 nide class that was previously used to treat type 2 diabetes.

48 lzheimer's disease, Parkinson's disease, and type 2 diabetes.

49 ing, particularly age at menarche (AAM), and type 2 diabetes.

50 macologic agents used to treat patients with type 2 diabetes.

51 reverse nonalcoholic fatty liver disease and type-2 diabetes.

52 is reduced at the onset of type-1 and during type-2 diabetes.

53 act surgery in patients with well-controlled type-2 diabetes.

54 994, and July 31, 2018, 45 072 patients with type 2 diabetes (21 936 [48.7%] female; mean age 56.7 ye

55 Among individuals with type 2 diabetes, ~30% exhibit hypomagnesemia.

56 In adults with type 2 diabetes, a lifestyle intervention is associated

57 id polypeptide (IAPP) forms islet amyloid in type 2 diabetes, a process which contributes to pancreat

58 sk of diabetic ketoacidosis in patients with type 2 diabetes: a systematic review and meta-analysis o

59 rter-2 inhibitors as combination therapy for type 2 diabetes: a systematic review and meta-analysis.

60 effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-an

61 cotransporter 2 inhibitors in patients with type 2 diabetes; a direct antithrombin agent, dabigatran

62 Type 2 diabetes accounts for 90% of the population with

63 Young adults with type 2 diabetes (aged 18-39 years) are at risk of early

64 We enrolled 111 subjects with type 2 diabetes (aged 58.5 +/- 8.9 y, 47% females, diabe

65 increasing number of patients suffering from type 2 diabetes, Alzheimer's disease, and diabetes-induc

66 should also be considered for patients with type 2 diabetes and a body mass index of 30 to 35 if hyp

67 ) with either established or newly diagnosed type 2 diabetes and additional cardiovascular risk facto

68 enal functional decline in a population with type 2 diabetes and advanced chronic kidney disease.

69 s should be advised to stop smoking to limit type 2 diabetes and CAD risk.

70 me (MetS) as a preceding metabolic state for type 2 diabetes and cardiovascular disease is widely rec

71 In this elderly cohort of patients with type 2 diabetes and chronic kidney disease, sTNFR1 predi

72 l glucose- and lipid-related biomarkers with type 2 diabetes and coronary artery disease.

73 axia (FRDA) include ataxia, muscle weakness, type 2 diabetes and heart failure, which are caused by i

74 nine aminotransferase) in the development of type 2 diabetes and hypertension (odds ratio, 1.59 and b

75 dict adverse renal outcomes in patients with type 2 diabetes and kidney disease (DKD) conventionally

76 onfigure disrupted metabolic inflammation in type 2 diabetes and nonalcoholic fatty liver disease by

77 ve glycemia and body weight in patients with type 2 diabetes and obesity but have limited weight-lowe

78 ys and the heart of patients with or without type 2 diabetes and preserved or reduced kidney function

79 rol and cardiovascular disease (CVD) risk in type 2 diabetes and to assess if the presence of cardio-

80 cebo-controlled trial included patients with type 2 diabetes and urine albumin-to-creatinine ratio 30

81 e pathogenesis of several diseases including Type 2 diabetes and various cancers.

82 ial target to decrease the risks of obesity, type 2 diabetes, and cardiovascular disease, and recent

83 recognized as a key risk factor for obesity, type 2 diabetes, and cardiovascular diseases.

84 ter adjusting for age, sex, body mass index, type 2 diabetes, and country.

85 es evaluating the risk of AKI in people with type 2 diabetes, and even fewer simultaneously investiga

86 ongly associated with obesity, dyslipidemia, type 2 diabetes, and metabolic syndrome.

87 Metformin is the first line of treatment for type 2 diabetes, and one of the underlying mechanisms fo

88 imetics are effective drugs for treatment of type 2 diabetes, and there is consequently extensive int

89 renal tubular cells is markedly impaired in type 2 diabetes, and this deficiency contributes importa

90 atic cancer include family history, obesity, type 2 diabetes, and tobacco use.

91 prevention and more intensive management of type 2 diabetes are urgently needed.

92 as assessed by PET/CT in 13 individuals with type 2 diabetes as part of a clinical study assessing th

93 However, other type 2 diabetes-associated SNPs that truncate SLC30A8 co

94 plex, EIF4EBP, and S6K in the circulation on type 2 diabetes, based on independent single nucleotide

95 uded: 52.5% with F4 NASH, 40% male, 72% with type 2 diabetes, baseline liver stiffness of 24.1 +/- 14

96 biting asprosin for treatment of obesity and type 2 diabetes, both of which are characterized by high

97 ll mass in the pathophysiology of type 1 and type 2 diabetes by enabling noninvasive quantification o

98 Thus the microbiota may contribute to type 2 diabetes by generating imidazole propionate that

99 morbidities that are influenced by NAFLD are type 2 diabetes, cardiovascular disease, and impaired ne

100 e been implicated as links between NAFLD and type 2 diabetes, cardiovascular disease, and neurocognit

101 ly associated with a higher risk of obesity, type 2 diabetes, cardiovascular disease, and premature m

102 ), and 32% (95% CI: 24, 39) lower hazards of type 2 diabetes compared with abstaining, respectively.

103 frequency domain BRS indices were reduced in type 2 diabetes compared with control 2 and were positiv

104 3) and 20% (95% CI: 3, 40) higher hazards of type 2 diabetes, compared with AAI 18.1-29.0 years and d

105 Thirty participants who have type 2 diabetes consume beverages that have identical in

106 The insidious onset of type 2 diabetes delays diagnosis and increases morbidity

107 Progression of CKD in type 2 diabetes, despite dual inhibition of sodium-gluco

108 These results indicate that, in type 2 diabetes, DKD is associated with reduced renal an

109 owed that the prescription of liraglutide, a type 2 diabetes drug, is significantly associated with d

110 Mean age was 74 years, with a median type 2 diabetes duration of 16 years.

111 Regarding type 2 diabetes framework, the extract inhibits alpha-gl

112 31 in gene TXNIP -previously associated with type 2 diabetes, glucose and lipid metabolism, associate

113 Type 2 diabetes had a higher risk for all cancer, HR 1.1

114 We measured plasma sTNFR1 in people with type 2 diabetes (HbA(1c) >= 48 mmol/mol) at 2 hospital s

115 lymorphism (SNP), rs10830963, associate with type 2 diabetes; however, whether they exert joint effec

116 re obesity and its related diseases, such as type 2 diabetes, hypertension, dyslipidemia, and sleep a

117 lic diseases (hypertriglyceridemia, obesity, type 2 diabetes, hypertension, metabolic syndrome), but

118 randomly assigned 5734 patients with CKD and type 2 diabetes in a 1:1 ratio to receive finerenone or

119 nsitivity and the disproportionate burden of type 2 diabetes in African Americans.

120 ventions to improve outcomes for adults with type 2 diabetes in LMICs.

121 abetic drug, is also effective in preventing type 2 diabetes in people at high risk(1,2).

122 adjusted for age, sex, body mass index, and type-2 diabetes in the phase 2 validation cohort, the mi

123 obiome have been associated with obesity and type 2 diabetes, in epidemiological studies and studies

124 A total of 457,473 patients with type 2 diabetes, included between 1998 and 2014, were ma

125 Both type 1 and type 2 diabetes increase the risk of atherosclerotic car

126 In patients with type 2 diabetes, increased dairy consumption to >=3 serv

127 on of groups at high risk for breast cancer, type 2 diabetes, inflammatory bowel disease, and coronar

128 ith high relevance in Alzheimers disease and type 2 diabetes interlink.

129 The worldwide dual epidemic of obesity and type 2 diabetes is an important public health issue.

130 a widely accepted definition of remission of type 2 diabetes is lacking.

131 management, beyond current programs in which type 2 diabetes is managed through diet, exercise, and m

132 e elevated levels of imidazole propionate in type 2 diabetes likely reflects altered microbial metabo

133 idence of metabolic abnormalities, including type 2 diabetes, low HDL, high triglycerides, and female

134 e found that health system interventions for type 2 diabetes may be effective in improving glycemic c

135 ing the plasma proteomes of individuals with type 2 diabetes may illuminate hitherto unknown function

136 hat post-disease-onset administration of the type 2 diabetes medication metformin reduces mitochondri

137 detection of muscle abnormalities related to type 2 diabetes mellitus (DM2) and DPN.PurposeTo assess

138 Most studies addressed type 2 diabetes mellitus (n = 85; 36%), hypertension (n

139 Type 1 and type 2 diabetes mellitus (T1DM and T2DM) increase the ri

140 Heart failure is a prominent complication of type 2 diabetes mellitus (T2D).

141 Currently, type 2 diabetes mellitus (T2DM) and obesity are major gl

142 tion is a well-described feature of obesity, type 2 diabetes mellitus (T2DM) and other insulin-resist

143 nt for every patient, why some patients with type 2 diabetes mellitus (T2DM) develop CVD while others

144 Obesity-associated type 2 diabetes mellitus (T2DM) entails insulin resistan

145 As the burden of type 2 diabetes mellitus (T2DM) grows in the 21st centur

146 Patients with Type 2 diabetes mellitus (T2DM) have an increased risk o

147 Men with type 2 diabetes mellitus (T2DM) have significantly lower

148 tural course of NAFLD (liver fat [LFAT]) and type 2 diabetes mellitus (T2DM) in HIV+ patients with an

149 Accumulating data suggest that type 2 diabetes mellitus (T2DM) in younger people (aged

150 Type 2 Diabetes mellitus (T2DM) is a disorder characteri

151 (AD) is a central nervous system disease and type 2 diabetes MELLITUS (T2DM) is a metabolic disorder,

152 The prevention of type 2 diabetes mellitus (T2DM) is a target priority for

153 Type 2 diabetes mellitus (T2DM) is an established risk f

154 Type 2 diabetes mellitus (T2DM) is associated with a hig

155 dic GLP-1 receptor agonists for treatment of type 2 diabetes mellitus (T2DM) motivated our search for

156 Patients with Type 2 diabetes mellitus (T2DM) show cognitive and mood

157 dies have shown that high-risk patients with type 2 diabetes mellitus (T2DM) treated with sodium gluc

158 dy to investigate the causal associations of type 2 diabetes mellitus (T2DM) with risk of overall can

159 strate the CVD safety of SGLT2 inhibitors in type 2 diabetes mellitus (T2DM), consistent reductions i

160 Type 2 diabetes mellitus (T2DM), dyslipidemia and period

161 ) the 78 pure spectra, presumably related to type 2 diabetes mellitus (T2DM), from their synthetic li

162 elopment of obesity-related diseases such as type 2 diabetes mellitus (T2DM), hypertension, and dysli

163 tive treatment for patients with obesity and type 2 diabetes mellitus (T2DM), there exists reluctance

164 llitus - type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM).

165 a third antidiabetic agent in patients with type 2 diabetes mellitus (T2DM).

166 hat increase the risk for the development of type 2 diabetes mellitus (T2DM).

167 d define eligibility criteria for those with type 2 diabetes mellitus (T2DM).

168 welve NGT subjects without family history of type 2 diabetes mellitus (T2DM; FH-) and 8 NGT with fami

169 paired glucose tolerance [IGT], and 207 with type 2 diabetes mellitus [T2DM]), divided in nonobese an

170 n certain obesity-linked diseases, including type 2 diabetes mellitus and atherosclerotic cardiovascu

171 d in states of perceived energy surplus (ie, type 2 diabetes mellitus and chronic heart failure), but

172 Twenty patients with type 2 diabetes mellitus and chronic, stable heart failu

173 lozin versus placebo in 17 160 patients with type 2 diabetes mellitus and either multiple risk factor

174 Type 2 diabetes mellitus and hypertension are the most c

175 Type 2 diabetes mellitus and hypertension are two major

176 Obesity and type 2 diabetes mellitus are global emergencies and long

177 icular specimens obtained from patients with type 2 diabetes mellitus as compared to nondiabetic subj

178 vents in primary prevention populations with type 2 diabetes mellitus is highly heterogeneous.

179 se (CVD), pharmacologic agents used to treat type 2 diabetes mellitus must show cardiovascular safety

180 -of small HDL was lower in the subjects with type 2 diabetes mellitus than the control subjects.

181 ar ejection fraction, 26%, and 12 (17%) with type 2 diabetes mellitus were randomized.

182 r, double-blind trial in which patients with type 2 diabetes mellitus who were recently hospitalized

183 riodontitis; (T2DMwell-DL-P) well-controlled type 2 diabetes mellitus with dyslipidemia and periodont

184 tis; and (T2DMpoorly-DL-P) poorly-controlled type 2 diabetes mellitus with dyslipidemia and periodont

185 score as a decision aid in individuals with type 2 diabetes mellitus without clinical atheroscleroti

186 thelium isolated from donors with obesity or type 2 diabetes mellitus, AGO1 and THBS1 are expressed a

187 y diseases, particularly insulin resistance, type 2 diabetes mellitus, and cardiovascular disease.

188 iew addresses the interplay between obesity, type 2 diabetes mellitus, and cardiovascular diseases.

189 ommon disease states including hypertension, type 2 diabetes mellitus, and chronic kidney disease.

190 The association of NASH with obesity, type 2 diabetes mellitus, and dyslipidemia has led to an

191 re associated with diseases such as obesity, type 2 diabetes mellitus, certain infections and some ca

192 wering therapies as first-line management of type 2 diabetes mellitus, considering heart failure or k

193 In patients with type 2 diabetes mellitus, ertugliflozin reduced the risk

194 s index, left ventricular ejection fraction, type 2 diabetes mellitus, history of myocardial infarcti

195 terol level, impaired fasting glucose level, type 2 diabetes mellitus, hypertension (HT), and metabol

196 s including cancer, cardiovascular diseases, type 2 diabetes mellitus, obesity, amnesia among other d

197 In patients with type 2 diabetes mellitus, sodium-glucose cotransporter 2

198 ding premature coronary heart disease, early type 2 diabetes mellitus, ubiquitous abdominal obesity,

199 enatide 2 mg versus placebo in patients with type 2 diabetes mellitus, while aiming for glycemic equi

200 FL adverse events in high-risk patients with type 2 diabetes mellitus.

201 as atherosclerosis, rheumatoid arthritis and type 2 diabetes mellitus.

202 that alcohol consumption is associated with type 2 diabetes mellitus.

203 ing drugs have improved our understanding of type 2 diabetes mellitus.

204 HF and cardiovascular death in patients with type 2 diabetes mellitus.

205 markedly changed the treatment landscape of type 2 diabetes mellitus.

206 sing target for the treatment of obesity and type 2 diabetes mellitus.

207 , pre-diabetic individuals and patients with type-2 diabetes mellitus (T2DM, n = 10 each).

208 the Mineralocorticoid Receptor Antagonist in Type 2 Diabetes (MIRAD) trial, which randomized patients

209 Importantly, beta-cells from db/db mice, a type 2 diabetes mouse model lacking functional leptin re

210 ed type 1 diabetes and high fat diet-induced type 2 diabetes mouse models and liver-specific Prmt1 de

211 udy baseline cohort with recent-onset type 1/type 2 diabetes (n = 206/381) and age-matched glucose-to

212 ion effects of these risk factors on odds of type 2 diabetes (n = 5,042 cases) and HbA(1c) levels (n

213 as severe (lipodystrophy, n = 14), moderate (type 2 diabetes, n = 9), or mild (obesity, n = 8).

214 ciated with increased risk of development of type 2 diabetes, nonalcoholic fatty liver disease (NAFLD

215 Remission of type 2 diabetes occurred in 66.7% (4/6) after SG and in

216 educed LV volumes in patients with HFrEF and type 2 diabetes or prediabetes.

217 ventricular (LV) ejection fraction <=40% and type 2 diabetes or prediabetes.

218 4, 95% CI: 1.12-1.37, P = 2 x 10-5), but not type 2 diabetes (OR 0.98, 95% CI: 0.89-1.08, P = 0.69),

219 leotide polymorphisms (SNPs) associated with type 2 diabetes overlap with putative endocrine pancreat

220 Single-center study of 94 patients with type 2 diabetes patients (157 eyes), divided into groups

221 Type 2 diabetes patients experienced a higher HR 1.23 (1

222 The increasing prevalence of type 2 diabetes poses a major challenge to societies wor

223 Type 2 diabetes predicts outcome following acute myocard

224 Adults with type 2 diabetes prescribed an SGLT2 inhibitor had a lowe

225 Thirty-eight patients with type 2 diabetes received an 8-h measurement of EGP ([3-(

226 study of 18,306 individuals with and without type 2 diabetes recruited between 1 December 1988 and 31

227 Association analysis of prevalent type 2 diabetes revealed 24 replicated proteins, of whic

228 sing insulin resistance, body mass index, or type 2 diabetes risk in African-ancestry populations.

229 and by the ablation of genes associated with type 2 diabetes risk in genome-wide association studies.

230 eby genetic determinants of smoking increase type 2 diabetes risk indirectly through their relationsh

231 ether they exert joint effects to exacerbate type 2 diabetes risk is unknown.

232 s have linked tobacco smoking with increased type 2 diabetes risk.

233 It maps to the PRC1 locus, a type 2 diabetes susceptibility locus, but its specific r

234 are lower in metformin-treated subjects with type 2 diabetes (T2D) and cardiovascular disease, yet ex

235 resistance (IR) precedes the development of type 2 diabetes (T2D) and increases cardiovascular disea

236 istance (IR) is an important risk factor for type 2 diabetes (T2D) and other cardiometabolic diseases

237 Psoriasis and type 2 diabetes (T2D) are complex conditions with signif

238 GDM) have a 7-fold higher risk of developing type 2 diabetes (T2D) during midlife and an elevated ris

239 Patients with type 2 diabetes (T2D) fail to secrete insulin in respons

240 e methods to the schizophrenia GWAS data and type 2 diabetes (T2D) GWAS meta-analysis summary data.

241 Attention to precision medicine in type 2 diabetes (T2D) has provided two favored approache

242 Patients with type 2 diabetes (T2D) have a lower risk of Mycobacterium

243 signals from a recent GWAS meta-analysis of type 2 diabetes (T2D) in Europeans.

244 The interplay between obesity and type 2 diabetes (T2D) in poststroke recovery is unclear.

245 ve been associated with reduced incidence of type 2 diabetes (T2D) in some studies.

246 tic loci associated with glycemic traits and type 2 diabetes (T2D) influence the response to antidiab

247 in Indians and misclassification of T1D and type 2 diabetes (T2D) is a particular problem in young a

248 Type 2 diabetes (T2D) is a progressive disease whereby t

249 The metabolic disease type 2 diabetes (T2D) is a risk factor for TB and the me

250 Type 2 diabetes (T2D) is associated with increased risk

251 Type 2 diabetes (T2D) is characterized by insulin resist

252 Type 2 diabetes (T2D) is defined by a single metabolite,

253 Type 2 diabetes (T2D) manifests from inadequate glucose

254 new molecular targets are key priorities in type 2 diabetes (T2D) research.

255 ting mitogen-activated protein kinases, as a type 2 diabetes (T2D) risk gene.

256 ia-inducible factors (HIFs) in hypertension, type 2 diabetes (T2D), and cognitive decline in experime

257 In obesity and type 2 diabetes (T2D), retinol binding protein 4 (RBP4),

258 In rodent models of type 2 diabetes (T2D), sustained remission of hyperglyce

259 re is emerging interest in multimorbidity in type 2 diabetes (T2D), which can be either concordant (T

260 -hydroxyvitamin D (25(OH)D) metabolites with type 2 diabetes (T2D), with total 25(OH)D and 25(OH)D3 i

261 a-cell degeneration, and the pathogenesis of type 2 diabetes (T2D).

262 to the development of insulin resistance and type 2 diabetes (T2D).

263 e physiologic pathways influence the risk of type 2 diabetes (T2D).

264 icrobiome is a promising target for managing type 2 diabetes (T2D).

265 single-nucleotide polymorphisms (SNPs) with type 2 diabetes (T2D).

266 omplications in individuals with and without type 2 diabetes (T2D).

267 ion and susceptibility to virus infection in type 2 diabetes (T2D).

268 TECs) derived from subjects with and without type 2 diabetes (T2D).

269 of impaired glucose tolerance to full blown type 2 diabetes (T2D).

270 00 signals robustly associated with risk for type 2 diabetes (T2D).

271 tified 13 taxa with disrupted rhythmicity in type 2 diabetes (T2D).

272 Type-2 diabetes (T2D) is a global disease caused by the

273 yloid deposits is a pathological hallmark of type-2 diabetes (T2D).

274 s (SCs) and skin biopsies from patients with type 2 diabetes (T2DM), we revealed the implication of L

275 scopies, 282 were performed on patients with type 2 diabetes (T2DM).

276 Type-2 diabetes (T2DM) leads to reduced myocardial perfo

277 cell growth and survival, but in people with type 2 diabetes the destructive effects of metabolic str

278 Despite being the frontline therapy for type 2 diabetes, the mechanisms of action of the biguani

279 is study involving patients with obesity and type 2 diabetes, the metabolic benefits of gastric bypas

280 g response could inform selection of optimal type 2 diabetes treatment in the near future.

281 Type 1 and advanced type 2 diabetes treatment involves daily injections or c

282 In patients with CKD and type 2 diabetes, treatment with finerenone resulted in l

283 We investigated whether the risk of type 2 diabetes varied with genetically predicted EIF-4E

284 ceived long-term insulin treatment and whose type 2 diabetes was inadequately controlled (glycated he

285 ingness preference and rs10830963 on risk of type 2 diabetes was seen, this interaction did not persi

286 In patients with type 2 diabetes, we also observed that intravenous infus

287 cohort study of participants with or without type 2 diabetes, we used electronic healthcare records t

288 Proteins showing association with incident type 2 diabetes were aminoacylase-1, growth hormone rece

289 ys were determined, and those in common with type 2 diabetes were identified.

290 Thirteen individuals with type 2 diabetes were studied after 4 weeks' treatment wi

291 h a history of GDM are at risk of developing type 2 diabetes which is a risk factor for periodontitis

292 Type 2 diabetes, which is mainly linked to obesity, is a

293 ed to improve the selection of patients with type 2 diabetes who may derive cardiovascular benefit fr

294 sets of consecutive participants with type 1/type 2 diabetes who reached the 5-year follow-up (n = 84

295 are frequently prescribed for patients with type 2 diabetes who suffer from dyslipidemia, are known

296 with obesity (body mass index >=30 kg/m) and type 2 diabetes who underwent metabolic surgery in an ac

297 the data of 16,624 Han Chinese patients with type 2 diabetes who were enrolled in 2007-2015.

298 that could be used to identify patients with type 2 diabetes who would derive benefit from fenofibrat

299 EIF-4E is associated with a lowered risk of type 2 diabetes with an odds ratio (OR) 0.94, 95% confid

300 e quality of life for people with type 1 and type 2 diabetes with reduced beta-cell function.